Natera

We’re on a mission to transform the management of disease worldwide.

[Natera @NateraGenetics]

This video reflects on the progress we’ve made, with a gracious nod to what comes next at Natera.

It brings together different perspectives, from how the outside world sees our work, to the voices of patients and families sharing what this experience looks like in their own words. It also reflects the work happening behind the scenes across teams and disciplines.

Most of us know someone impacted by cancer, planning for a baby, or navigating life after a transplant. It’s something we think about every day, and we’re honored to support people through some of life’s most important moments.

We’re proud of the progress. Grateful for the trust patients place in us. And clear on how much more there is to do.

If you have a few minutes, it’s worth a watch.

[Natera @NateraGenetics]

In observance of Pregnancy and Infant Loss Awareness Month, Dr. Shahin Ghadir, Reproductive Endocrinology & Infertility Specialist, shares what patients should know after experiencing pregnancy loss. #YouAreNotAlone

@drshahinghadir

[Natera @NateraGenetics]

Don't miss this upcoming webinar where our experts will discuss the ctDNA signal for immunotherapy response. You'll learn more about Signatera™, a personalized ctDNA assay that works broadly as a real-time treatment response biomarker, sensitive enough to pick up small shifts in disease burden that precede imaging changes.

Register here: https://t.co/tUWugYYyJJ

[Natera @NateraGenetics]

Read about the data and presentations in our press release: https://t.co/unpD0kxAa8

#ESMO26

[Natera @NateraGenetics]

At this year’s European Society for Medical Oncology (ESMO) Annual Congress, we’re sharing exciting progress in precision oncology. Twenty abstracts, including four rapid oral presentations, feature Natera technology across multiple tumor types and treatment modalities.

Learn more about our expanding diagnostics portfolio on our website and connect with us at booth 1015 during the meeting.

https://t.co/qpBnBJZO2K

#ESMO26 @myESMO

[Steve Chapman @SteveChapmanCEO]

Signatera has been named one of @TIME's Best Inventions for 2026.

I keep coming back to how this started. An idea with enormous promise, and plenty of people who thought it was ahead of its time. Building something that doesn't exist means a lot of long days, hard questions, and the temptation to settle.

The @NateraGenetics team never settled. Scientists who held the line on quality in the lab. Researchers who committed to best-in-class evidence. People who kept the patient in mind with every test, because behind every result is someone waiting to hear what comes next.

One of the biggest problems in cancer care is knowing who needs additional therapy and who might safely avoid it. Signatera can help guide those challenging decisions, because it can detect disease recurrence in the blood up to two years in advance of imaging, giving patients and their doctors greater lead time.

TIME looked for originality, efficacy, ambition, and impact, and we are proud to have met this high bar. This honor belongs to the patients, clinicians, and Natera team members who made it possible.

This is a great recognition, and importantly, we know our best work remains ahead.

https://t.co/ztgUN0IpXl

#Signatera #MRD #Oncology #TIMEBestInventions

[Natera @NateraGenetics]

Join David Russler-Germain, MD, PhD (@dgermain21) and Rod Ramchandren, MD, for a live discussion of new real-world data from Galanina et al., Blood Neoplasia 2026, the largest real-world study of ctDNA-based MRD testing in lymphoma, spanning 144 patients across 14 subtypes. Explore what these findings may mean for monitoring patients in everyday practice.

Register here: https://t.co/mxKEoJc0Fb

[Natera @NateraGenetics]

We’re honored to share that our Signatera™ test has been named to @TIME's Best Inventions of 2026 list. The annual list features life-changing innovations evaluated on originality, efficacy, ambition, and impact.

Signatera is a personalized, molecular residual disease (MRD) test for patients diagnosed with cancer. Built from the unique genomic signature of each patient’s tumor, Signatera detects and quantifies tiny fragments of circulating tumor DNA (ctDNA) in the blood, providing ongoing monitoring for disease recurrence and response to treatment across cancer types. The test also plays an important role in oncology drug development, helping pharmaceutical companies identify patients for clinical trials and accelerate the approval of novel therapies.

Read more: https://t.co/9bJnxrqlm1

#TIMEBestInventions #Natera #Signatera

[TransCode Therapeutics @RNAoncology]

@NateraGenetics and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

https://t.co/2zkzju3ch0

[Natera @NateraGenetics]

Chance Osborne, marketing manager on our oncology patient engagement team and triple negative breast cancer survivor, recently shared her story with @USATODAY, including how she uses Signatera™ every three months to monitor her health in survivorship.

Thank you, Chance, for your openness and for inspiring others this #BreastCancerAwarenessMonth.

https://t.co/8JQFPbsN0S

[Natera @NateraGenetics]

Today we are shining a light on Matt Moyer. Matt is a staff biostatistician at Natera, where he designs rigorous validation studies to support our growing product portfolio. His work focuses on tests within organ health and women’s health.

For Matt, this work hits close to home. While researching Natera during the interview process in 2021, he discovered Prospera™ Kidney and thought there should be a test like this for lung transplant patients, like his mom. He then learned that the development of Prospera™ Lung was underway, and his first project became its validation. When he shared his family's story, a colleague captured the team's commitment perfectly: “We have to get this right for Matt's mom.”

[Natera @NateraGenetics]

@FortuneMagazine's “Future 120” list has just been released and we’re honored to be recognized. This list highlights companies across industries poised to define the next chapter of business and innovation.

Every day, our team is focused on advancing the technology and solutions to support the patients who need it most.

https://t.co/phtC1JcPQP

[Natera @NateraGenetics]

Four of our abstracts were selected for oral presentations at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, showcasing the expanding clinical utility of Signatera™ across tumor types and treatment settings.
Learn more about our latest data: https://t.co/BO39ua7Gpa
#ASTRO26 @ASTRO_org

[Natera @NateraGenetics]

Natera is proud to be the 2026 Premier National Series Sponsor of the @SusanGKomen Race for the Cure® and MORE THAN PINK Walk® events.

So far, we’ve walked with you at the:
📍 Komen Seattle MORE THAN PINK Walk
📍 Komen Omaha MORE THAN PINK Walk
📍 Komen Tulsa Race for the Cure
📍 Komen Wisconsin MORE THAN PINK Walk
📍 Komen Orange County MORE THAN PINK Walk
📍 Komen Indianapolis MORE THAN PINK Walk
📍 Komen Houston Race for the Cure
📍 Komen Central Jersey MTPW

This partnership combines Natera’s leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen’s global advocacy and patient support network.

Join us on the ground in cities across the nation as we walk, fundraise, and show up for everyone impacted by breast cancer. 🎗️

[Natera @NateraGenetics]

Join our upcoming webinar to hear from Jeffrey Meltzer MD, MBA FACOG, principal medical director, Natera and Samantha Brummitt, MS CGC, senior medical science liaison, Natera, on the implications of updated American Society for Reproductive Medicine (ASRM) guidelines and how Anora™, a comprehensive products of conception (POC) miscarriage test, can provide insight into the cause of pregnancy loss and help guide future reproductive decisions.

Join our webinar to learn about:
• How Anora, Natera’s SNP-based miscarriage test, aligns with the new ASRM guidance for recurrent pregnancy loss evaluation
• The clinical and logistical advantages of Anora that can help provide meaningful results for patients
• Case studies illustrating how Anora results can help guide individualized reproductive care plans, including a personal story from our speaker Samantha Brummitt

Register here: https://t.co/lZnAbMArnn

[Natera @NateraGenetics]

@beachboyhhi Hello. We'd like to follow up on this feedback and see how we can best help resolve it. For support, please email [email protected]. Thank you. ^LG

[Natera @NateraGenetics]

This is incredibly important research that will use Signatera™ to help individualize treatment for patients with breast cancer. We’re proud to support this work alongside @ALLIANCE_org and @genentech, and grateful to the patients and investigators making it possible.

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

Alliance Foundation Trials and Natera have launched AFT-70 NAVIGATE, a global Phase III trial in ER+/HER2- early-stage breast cancer, evaluating giredestrant, Genentech’s investigational oral SERD, with Signatera™ MRD-guided CDK4/6 inhibitor therapy: https://t.co/OpUPjsSkGi

[Natera @NateraGenetics]

Watch below 👇

[Natera @NateraGenetics]

By combining standard sequencing with advanced long-read technology, our Zenith™ platform provides deeper insights to help reach a definitive diagnosis for patients with specific variants.

In this clip, Dr. Danny Miller of Seattle Children’s Hospital and University of Washington explains why this matters: When a DNA repeat is longer than the read itself, you can't measure how long it is. You can also miss sequence interruptions entirely — and they can be clinically important.

Long-read sequencing solves this problem because the reads are simply long enough to span the entire repeat. This means you can accurately measure the repeat length and detect those interruptions that short reads might miss.

For the many pediatric neurogenetic conditions that involve tandem repeat expansions, this makes a real difference. https://t.co/AC00YgNVVH

[Natera @NateraGenetics]

Our CEO, @SteveChapmanCEO, recently sat down with Jonathan Palmer, host of the podcast, Vanguards of Healthcare by Bloomberg Intelligence, for a thoughtful discussion on Natera. Steve was one of Natera’s earliest employees, when the company was much smaller and focused solely on women’s health. Since that time, Natera has branched into organ health, oncology, and rare disease, becoming a precision medicine leader. As noted in the podcast summary:

“‘Clinical data is the key to being successful in diagnostics,’ Steve Chapman, CEO of Natera, tells Bloomberg Intelligence analyst Jonathan Palmer as he explains how an early bet on evidence helped turn a small genetic-testing company into a broad diagnostics platform. Chapman traces Signatera™ from a side project into a leading minimal residual disease (MRD) test and details Natera’s nearly $1 billion R&D investment to push into genome-based testing, early cancer detection and new indications. The conversation also explores the next layer of value from Natera’s platform — millions of longitudinal data points, AI-enhanced test results and patient experiences, more efficient biopharma trials and the potential to use neoantigen prediction algorithms to support personalized cancer vaccines.”

Listen in for more. https://t.co/rd80vo0IMJ

@business @Bloomberg @BBGIntelligence